TUCSON, Ariz.--(BUSINESS WIRE)--Calimmune Inc., a clinical-stage gene therapy company, today announced the appointment of R. Scott Greer as chairman of its board, and AbbVie Vice President of Discovery James Sullivan, Ph.D., as a new director. Mr. Greer will serve as chairman, replacing David Baltimore, Ph.D., who will remain active with Calimmune as a board member.
